Nanjing Jicui Jiding Pharmaceutical

Nanjing Jicui Jiding Pharmaceutical Co., Ltd. is a specialty pharmaceutical company based in Nanjing, China, that focuses on the development and commercialization of advanced drug delivery systems and novel formulations. Established in 2020 under the Jiangsu Jicui Novel Pharmaceutical Formulation Technology Research Institute, the company utilizes its proprietary formulation platforms to develop high-compliance dosage forms such as oral soluble films, dry syrups, and orally disintegrating tablets. Its pipeline features CMC-2310, a brexpiprazole oral soluble film co-developed with Fosun Pharma for schizophrenia, alongside several advanced generic or improved formulations including procaterol hydrochloride dry syrup for asthma and vardenafil hydrochloride orally disintegrating tablets for erectile dysfunction. By transforming traditional oral medications into patient-friendly formats, the company aims to address critical clinical needs in respiratory, central nervous system, and metabolic disorders.